|Bid||5.76 x 800|
|Ask||19.50 x 800|
|Day's range||14.20 - 15.10|
|52-week range||12.48 - 37.17|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||04 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||28.60|
Treace Medical Concepts, Inc. ( NASDAQ:TMCI ) shareholders should be happy to see the share price up 13% in the last...
Participating from the company today will be John Treace, chief executive officer; and Mark Hair, chief financial officer. Before we begin, we would like to remind you that it is our intent that all forward-looking statements made during this call will be protected under the Private Securities Litigation Reform Act of 1995. Any statements that relate to expectations or predictions of future events and market trends, as well as our estimated results or performance, are forward-looking statements.
Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of 20% and 10.95%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?